Potent activity of 2'-β-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 10, 1996, Pages 2369-2374

  Ruxrungtham, Kiat ^a,d   Boone, Elizabeth ^a   Ford Jr , Harry ^b   Driscoll, John S ^b   Davey Jr , Richard T ^a   Lane, H Clifford ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; ANTIVIRUS AGENT; ZIDOVUDINE;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPLEEN CELL; VIRUS ISOLATION;

EID: 0029816732     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.10.2369     Document Type: Article

References (23)

1. Barchi, J. J., Jr., V. E. Marquez, J. S. Driscoll, H. Ford, Jr., H. Mitsuya, T. Shirasaka, S. Aoki, and J. A. Kelley. 1991. Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 34:1647-1655.
2. Boyle, M. J., M. Connors, M. E. Flannigan, S. P. Geiger, H. Ford, Jr., M. Baseler, J. Adelsberger, R. T. Davey, Jr., and H. C. Lane. 1995. The Hu-HIV/PBL-SCID mouse: a modified Hu-PBL-SCID model for the study of HIV pathogenesis and therapy. J. Immunol. 154:6612-6623.
3. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, P. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:431-438.
4. Cooney, D. A., M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Baizarini, S. Broder, and D. G. Johns. 1986. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35:2065-2068.
5. Fultz, P. N. 1993. Nonhuman primate models for AIDS. Clin. Infect. Dis. Suppl. 1, p. S230-S235.
6. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
7. Ho, H.-T., and M. J. M. Hitchcock. 1989. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:844-849.
8. Koenig, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, C. Carter, J. Yanelli, S. A. Rosenberg, and H. C. Lane. 1995. Adoptive transfer of an autologous HIV-specific CTL clone to a patient with AIDS selects for HIV variants with deletions within a CTL epitope. Nat. Med. 1:330-336.
9. Lane, H. C., H. Masur, E. P. Gelmann, D. L. Longo, R. G. Steis, T. Chused, G. Whalen, and A. S. Fauci. 1985. Immunologic profiles define clinical subpopulations of patients with the acquired immunodeficiency syndrome. Am. J. Med. 78:417-422.
10. Marquez, V. E., C. K. Tseng, J. A. Kelley, H. Mitsuya, S. Broder, J. S. Roth, and J. S. Driscoll. 1987. 2′,3′-Dideoxy-2′-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36:2719-2722.
11. Marquez, V. E., C. K. Tseng, H. Mitsuya, S. Aoki, J. A. Kelley, H. Ford, Jr., J. S. Roth, S. Broder, D. G. Johns, and J. S. Driscoll. 1990. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J. Med. Chem. 33:978-985.
12. Masood, R., G. S. Ahluwalia, D. A. Cooney, A. Fridland, V. E. Marquez, J. S. Driscoll, Z. Hao, H. Mitsuya, C. F. Perno, S. Broder, et al. 1990. 2′-Fluoro-2′,3′-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2′,3′-dideoxyadenosine. Mol. Pharmacol. 37:590-596.
13. McCune, J. M., R. Namikawa, H. Kaneshima, L. D. Shultz, M. Lieberman, and I. L. Weisman. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639.
14. McCune, J. M., R. Namikawa, C. C. Shih, L. Rabin, and H. Kaneshima. 1990. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247:565-566.
15. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 83:1911-1915.
16. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
17. Mitsuya, H., R. Yarochoan, and S. Broder. 1990. Molecular targets for AIDS therapy. Science 249:533-544.
18. Mosier, D. E., R. J. Gulizia, S. M. Baird, and D. B. Wilson. 1988. Transfer of a functional immune system to mice with severe combined immunodeficiency. Nature (London) 335:256-259.
19. Mosier, D. E., R. J. Gulizia, S. M. Baird, D. B. Wilson, D. H. Spector, and S. A. Spector. 1991. Human immunodeficiency virus infection of human PBL-SCID mice. Science 251:791-794.
20. Mosier, D. E., R. J. Gulizia, P. D. MacIsaac, L. Corey, and P. D. Greenberg. 1993. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc. Natl. Acad. Sci. USA 90:2443-2447.
21. Pantaleo, G., C. Graziosi, L. Butini, P. A. Pizzo, S. M. Schnittman, D. P. Kotler, and A. S. Fauci. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:9838-9842.
22. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 362:355-358.
23. Shih, C. C., H. Kaneshima, L. Rabin, R. Namikawa, P. Sager, J. McGowan, and J. M. McCune. 1991. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J. Infect. Dis. 163:625-627.